

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1683]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

At consultation the company highlighted the potential for poorer outcomes in people with squamous NSCLC caused by smoking-related comorbidities. It suggested this was likely to have an impact upon people in lower socio-economic groups due to higher rates of smoking in this group of people.

The committee noted it had no evidence to suggest outcomes would differ for this group of people compared with those who had other cancers. The committee concluded there are no equalities issues and all relevant benefits of the technology were captured in the QALY.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 3.16 of the FAD

Approved by Associate Director (name): Jasdeep Hayre

Date: 8 November 2021